FY2025 · ended Dec 31, 2025 · Revenue $170.16M, -25.1% YoY · Filed Feb 26, 2026
Ginkgo Bioworks Holdings, Inc. (DNA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $170.2 million and a net loss of $312.8 million. Free cash flow was -$178.7 million. As of Jun 30, 2026 it held $302.2 million in cash and investments and $404.1 million in total debt.
Revenue (TTM)
$132.42M
-37.0% vs year-ago TTM
Net income
$-312.76M
+42.8% vs prior year
Operating cash flow (TTM)
$-170.24M
+28.4% vs year-ago TTM
Free cash flow (TTM)
$-174.80M
+36.2% vs year-ago TTM
EPS
$-5.64
+46.5% vs prior year
Dividend per share
None
Shares outstanding
58.21M
+7.1% vs prior year
Net cash
$-101.95M
as of Jun 30, 2026
Operating margin
-231.1%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DNA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1830214
- Former names
- Soaring Eagle Acquisition Corp. (until Sep 17, 2021); Spinning Eagle Acquisition Corp. (until Jan 4, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M |
| Operating income | -$315.3M | -$559.8M | -$864.4M | -$2.2B | -$1.8B |
| Net income | -$312.8M | -$547.0M | -$892.9M | -$2.1B | -$1.8B |
| Diluted EPS | -$5.64 | -$10.54 | -$18.37 | -$50.20 | -$1.39 |
| Operating cash flow | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M |
| Free cash flow | -$178.7M | -$382.1M | -$336.3M | -$304.5M | -$310.3M |
| Total assets | $1.1B | $1.4B | $1.7B | $2.5B | $2.1B |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803.0M | $503.6M |
| Stockholders' equity | $508.6M | — | — | $1.7B | $1.5B |
| Cash and investments | $422.6M | $561.6M | $944.1M | $1.3B | $1.6B |
| Total debt | $439.9M | $467.8M | $242.2M | $444.1M | $22.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1000 Ginkgo Bioworks Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.